Trial · NCT07357103
Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)
NCT07357103, Phase 4, Not yet recruiting, McGill University Health Centre/Research Institute of the McGill University Health Centre
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives). Trials, record NCT07357103. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07357103
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)
- NCT number
- NCT07357103
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 416 participants, estimated
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Conditions
Pneumocystis, Pneumocystis Infection, Pneumocystis Carinii Infection, Pneumocystis Carinii; Infection, Resulting From HIV Disease, Pneumocystis Jirovecii Pneumonia, Pneumocystis Jirovecii Infection, Pneumocystosis Associated With AIDS, Pneumocystosis; Pneumonia (Etiology)
- Interventions
- Clindamycin + primaquine, Pentamidine, Atovaquone
- First posted
- 2026-01-21
- Last updated
- 2026-01-21
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hierarchical composite outcome | Day 30 | Hierarchical composite of Win Ratio at day 30: * death; * new extracorporeal membrane oxygenation (ECMO), * new invasive mechanical ventilation; * severe (CTCAE grade 4) adverse drug event (dermatologic, nephrologic, hematologic, neurologic, and/or endocrinologic) considered at least probable (by Leape and Bates criteria); * new non-invasive ventilation; * change of therapy (i.e., dose or agent) due to presumed treatment failure or probable adverse drug reaction (by Leape and Bates criteria); and * length of stay in hospital (amongst survivors) |
| Secondary | Proportion of patients that die (death) | Day 30 | Mortality at day 30 |
| Secondary | Proportion of patients with a need for new extracorporeal membrane oxygenation (ECMO), | Day 30 | New initiation of extracorporeal membrane oxygenation during hospitalization following initiation of assigned PCP treatment strategy. |
| Secondary | Proportion of patients requiring new Invasive Mechanical Ventilation | Day 30 | Initiation of invasive mechanical ventilation via endotracheal intubation during hospitalization following initiation of the assigned PCP treatment strategy. |
| Secondary | Proportion of patients with severe (CTCAE grade 4) adverse drug event | Day 30 | Proportion of patients with occurence of severe (CTCAE grade 4) adverse drug event (dermatologic, nephrologic, hematologic, neurologic, and/or endocrinologic) considered at least probable (by Leape and Bates criteria). |
| Secondary | Proportion of patients with need for new non-invasive ventilation; | Day 30 | initiation of non-invasive ventilation (including continuous positive airway pressure \[CPAP\] or bilevel positive airway pressure \[BiPAP\] during hospitalization following initiation of the assigned PCP treatment strategy. |
| Secondary | Proportion of patients requiring escalation or change of PCP -directed therapy | Day 30 | Proportion of patients with escalation or change of PCP -directed therapy due to inadequate clinical response, disease progression, or treatment-limiting toxicity during the treatment or follow-up period. |
| Secondary | Median length of stay in hospital amongst survivors | Day 30 | Length of hospital stay, measured in days from hospital admission to discharge among participants who survive to hospital discharge. |
| Other | Tertiary outcome measure of quality of life at day 30 | Day 30 | Quality of life (EQ-5D-5L) wherein a higher score indicates better quality of life. |
| Other | Tertiary outcome measure of all-cause mortality | Day 180 | All-cause mortality, defined as death from any cause. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07357103
GET https://conductscience.org/api/trials/v1/NCT07357103/registered